Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cytarabine + tosedostat in previously untreated older patients with acute myeloid leukemia
2012-000334-19Phase 2Active
- Sponsor
- San Salvatore Hospital of L'Aquila
- Start
- Aug 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tosedostat and cytarabine in acute myeloid leukemia (AML), sponsored by San Salvatore Hospital of L'Aquila. Primary endpoint: Complete remission rate. Started Aug 2012; status: active.
02
Drugs
tosedostatcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2012-000334-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000334-19.